Immunic, Inc. (IMUX)
After hours:
| Previous close | 1.0200 |
| Open | 1.0400 |
| Bid | 1.1100 x 400 |
| Ask | 1.1400 x 400 |
| Day's range | 1.0300 - 1.1300 |
| 52-week range | 0.9450 - 3.1100 |
| Volume | |
| Avg. volume | 245,368 |
| Market cap | 99.988M |
| Beta (5Y monthly) | 1.83 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Immunic to Participate in Industry and Scientific Conferences in June
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following industry and scientific conferences in June:
- PR Newswire
Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced financial results for the first quarter ended March 31, 2024, and provided a corporate update.
- PR Newswire
Immunic to Participate in Investor and Scientific Conferences in May
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in May:
